Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Nanoform in connection with its capital raising and listing on Nasdaq First North Premier Growth markets Finland and Sweden
Mandate

Vinge advises Nanoform in connection with its capital raising and listing on Nasdaq First North Premier Growth markets Finland and Sweden

June 04, 2020 Capital Markets and Public M&A

Vinge has advised Nanoform Finland Plc (“Nanoform”) in connection with its capital raising and listing on Nasdaq First North Premier Growth markets Finland and Sweden.

The prospectus was published on 25 May 2020 and the trading on Nasdaq First North Premier began on 4 June 2020. The total value of the offering amounted to approximately EUR 88 million, assuming that the over allotment option is fully exercised.
 
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services.
 
Vinge’s team primarily consisted of Dain Hård Nevonen, Rikard Lindahl, Hampus Olsson and Julia Hirschberg. 
 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025